Ardsley Advisory Partners’s Lipocine LPCN Stock Holding History

Ardsley Advisory Partners’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-588	Closed	-$34K	–	159
2017 Q4	$34K	Buy	+588	New	+$36.6K	﹤0.01%	136

Other funds holding LPCN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Ardsley Advisory Partners's LPCN Position: Q1 2018 in Review

Ardsley Advisory Partners sold out of Lipocine (LPCN) in Q1 2018, closing a stake of 588 shares — an estimated $34K sold.

Ardsley Advisory Partners first reported a position in LPCN in Q4 2017 and held it in 1 quarter. The position peaked at $34K in Q4 2017. 27 funds tracked by Wall St. Rank hold LPCN as of Q1 2018.

Ardsley Advisory Partners reported no remaining Lipocine position as of Q1 2018 after selling out during the quarter.
Ardsley Advisory Partners sold 588 Lipocine shares in Q1 2018, an estimated $34K.
Ardsley Advisory Partners first reported a position in Lipocine in Q4 2017 and held it in 1 quarter.
Ardsley Advisory Partners's Lipocine position peaked at $34K in Q4 2017.
27 funds tracked by Wall St. Rank held Lipocine as of Q1 2018.

Based on Ardsley Advisory Partners's 13F filing for Q1 2018, filed 15 May 2018.